Octodrine (Vaporpac) is a stimulant drug whose pharmacology was studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the FDA as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral agent as part of a multicomponent medication (i.e., Ambredin and Ordinal), but is no longer available.
|Other names||Ottodrina; Vaporpac; Amidrine; 2-Amino-6-methylheptane; 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-Methyl-2-heptanamine|
|CompTox Dashboard (EPA)|
|ECHA InfoCard||100.008.047 |
|Chemical and physical data|
|Molar mass||129.24 g/mol g·mol−1|
|3D model (JSmol)|
Octodrine has also been found as an adulterant in sports supplements.
- CID 10982 from PubChem
- Cohen, Pieter A.; Travis, John C.; Keizers, Peter H. J.; Deuster, Patricia; Venhuis, Bastiaan J. (8 November 2017). "Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA)". Clinical Toxicology. 56 (6): 421–426. doi:10.1080/15563650.2017.1398328.